Patients treated for differentiated thyroid cancer with negative 131I whole-body scanning and elevated thyroglobulin levels. A possible course;Pacientes tratados por carcinoma diferenciado de tiroides con rastreos de 131I negativos y niveles de tiroglobulina elevada. Una evolución posible

Revista Espanola de Medicina Nuclear

Volumn 26, Issue 3, 2007, Pages 138-145

  Gutierrez Cardo A L ^a   Rodriguez Rodriguez J R ^a   Borrego Dorado, I ^a   Navarro Gonzalez E ^a   Tirado Hospital, J L ^a   Vazquez Albertino R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Radioiodine; Thyroglobulin; Thyroid neoplasms

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN;

ADULT; AGED; ARTICLE; DIAGNOSTIC IMAGING; DIFFERENTIATED THYROID CANCER; DISEASE COURSE; DRUG MEGADOSE; FEMALE; FOLLICULAR CARCINOMA; FOLLOW UP; HISTOLOGY; HORMONAL THERAPY; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; PAPILLARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; WHOLE BODY SCINTISCANNING;

EID: 34347358669     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13102483     Document Type: Article

References (22)

1. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, et al. Follow-up of low risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150:105-12.
2. Ashcraft MW, van Herle AJ. The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiaed thyroid cancer. Am J Med. 1981;71:806-14.
3. Ma Ch, Xie J, Kuang A. Is empiric 1311 therapy justified for patients with positive thyroglobulin and negative 131I whole-body scanning results? J Nucl Med. 2005;46:1164-70.
4. De Keizer B, Koppeschaar HP, Zelissen PM. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med. 2001;28:198-202.
5. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-63.
6. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger MJ. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? Clin Endocrinol Metab. 2000;85:175-8.
7. Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005; 46:28S-37S.
8. Nemec J, Zamrazil V, Pohunkova D, Röhling S. Radioiodide treatment of pulmonary metastases of differentiated thyroid cancer: results and prognostic factors. Nuklearmedizin. 1979;18: 86-90.
9. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88: 1433-41.
10. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803.
11. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, et al. Therapeutic doses of Iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med. 1987;28:1888-91.
12. Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273-6.
13. Ma C, Kuang A, Xie J, Ma T. Possible explanations for patients with discordant findings of serum thyroglobulin and 131I whole-body scanning. J Nucl Med. 2005;46:1473-80.
14. Dohan O, Carrasco N. Advances in Na+ /I-symporter (NIS) research in the thyroid and beyond. Mol Cell Endocrinol. 2003; 213:59-70.
15. Arnstein NB, Carey JE, Spaulding SE, Sisson JC. Determination of Iodine-131 diagnostic dose for imaging metastatic thyroid cancer. J Nucl Med. 1986;27:1764-69.
16. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab. 1995;80: 1488-92.
17. De Keizer B, Koppeschaar H, Zelissen P, Lips C, van Rijk P, Dijk A, et al. Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin. Eur J Nucl Med. 2001;28:198-202.
18. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA. Lack of impact of radioiodine therapy in Tg-positive diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab. 2002;87:1521-6.
19. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638-44.
20. De Vathaire F, Schlumberger M, Delisle MJ, Francese C, Challeton C, de la Genardiere E, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer. 1997;75:734-9.
21. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: comparison of patients treated with hig 131I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86:4092-7.
22. Ruiz J, Borrego I, Gómez P, Rodríguez J, Vázquez R, Navarro E, et al. PET con 18FDG en pacientes con cáncer diferenciado de tiroides que presentan niveles elevados de tiroglobulina sérica y rastreos con 131I negativos. Rev Esp Med Nucl. 2005;24:5-13.